Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND‐XR
Andrology · 25.05.2026
DOI: 10.1111/andr.70263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Andrology, online erschienen am 25.05.2026. Verfasst von Mohamad M Saab und 30 weiteren Autor:innen. Beteiligte Einrichtung: Catherine McAuley School of Nursing and Midwifery, University College Cork, Cork, Ireland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the European Union, HORIZON EUROPE Health.
Abstract (Originalsprache)
Background
Testicular cancer (TC) is the most common malignancy amongst adolescents and young adults (AYAs) aged 15–39 years assigned male at birth. Survivors often experience late effects of treatment and report unmet supportive care needs.
Objectives
To present the protocol for the TRANSCEND‐XR project (TesticulaR cANcer late effects and unmet Supportive CarE NeeDs of AYA survivors using eXtended Reality). Materials and Methods TRANSCEND‐XR aims to ethically co‐create, test, and scale up in a clinical setting an innovative digital intervention to increase AYA TC survivors’ knowledge of the late effects of TC treatment and address their unmet supportive care needs using XR. Delivered by a consortium of 15 partners across 12 European countries, guided by the Medical Research Council's framework for complex interventions, and funded by the European Union, TRANSCEND‐XR is structured into three phases: co‐creation and validation (Phase 1); implementation and evaluation (Phase 2); and impact, guideline development, policy, dissemination, and exploitation (Phase 3).
Results
Phase 1 involves a cross‐sectional survey of 500 AYA TC survivors to assess late effects and care needs as well as participatory World Café sessions with healthcare professionals, survivors, and care partners ( n = 200) to co‐design the TRANSCEND‐XR intervention. Phase 2 includes a multicentre, single‐arm phase 2 pilot trial ( n = 15) across three clinical sites in three countries evaluating intervention feasibility, and a multicentre pragmatic randomised controlled phase 3 trial ( n = 230) across eight clinical sites in seven countries, evaluating improvements in knowledge of late effects, cost‐effectiveness, implementation, and ethical considerations. Phase 3 focuses on guideline development, policy influence, and strategic dissemination to ensure long‐term sustainability and integration into European healthcare systems.
Discussion
TRANSCEND‐XR aims to transform survivorship care for AYA TC survivors through a co‐created, scalable XR intervention. Its interdisciplinary approach promotes scientific rigour, stakeholder engagement, and policy relevance to improve long‐term outcomes and quality of life.
Conclusion
TRANSCEND‐XR has the potential to advance survivorship care standards for AYAs with TC whilst providing a model for future digital health interventions in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Catherine McAuley School of Nursing and Midwifery, University College Cork, Cork, Ireland.
- Cancer Research Centre, College of Medicine and Health, University College Cork, Cork, Ireland.
- Cork University Hospital/University College Cork Cancer Centre, Cork University Hospital, Cork, Ireland.
- School of Computer Science and Information Technology, University College Cork, Cork, Ireland.
- School of Public Health, University College Cork, Cork, Ireland.
- Health Research Board Clinical Research Facility, University College Cork, Cork, Ireland.
ORCID-Profile: Mohamad M Saab, Josephine Hegarty, Joanne Reid, Paulo Alves, Maria O'Malley
Förderung
- the European Union
- HORIZON EUROPE Health
Zitieren
APA
Saab, M. M., Hegarty, J., Gleeson, J. P., Murphy, D., McHugh, S., Shiely, F., Murphy, A., Kirby, A., Korfage, I. J., Terhaard, S., van der Heide, A., Sivesgaard, J., Seidler, M. K., Patrikidou, A., Ježek, D., Corrigan, L., Sheehan, P. K., Raggi, D., Reid, A., …, & O'Malley, M. (2026). Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND‐XR. Andrology. https://doi.org/10.1111/andr.70263
Vancouver
Saab MM, Hegarty J, Gleeson JP, Murphy D, McHugh S, Shiely F, et al. Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND‐XR. Andrology. 2026. doi:10.1111/andr.70263
BibTeX
@article{Saab2026,
author = {Saab, Mohamad M and Hegarty, Josephine and Gleeson, Jack P and Murphy, David and McHugh, Sheena and Shiely, Frances and Murphy, Aileen and Kirby, Ann and Korfage, Ida J and Terhaard, Sophie and van der Heide, Agnes and Sivesgaard, Johannes and Seidler, Matias Katajavaara and Patrikidou, Anna and Ježek, Davor and Corrigan, Lynda and Sheehan, Patrice Kearney and Raggi, Daniele and Reid, Alison and Chovanec, Michal and Gianntempo, Patrizia and Gietema, Jourik A and van der Feen, Justine Fleur and Lupiáñez-Villanueva, Francisco and Roca-Umbert, Ana and Reid, Joanne and Alves, Paulo and Soares, Joana and Galvin, Karen and Kubo, Michal and O'Malley, Maria},
title = {Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND‐XR},
journal = {Andrology},
year = {2026},
doi = {10.1111/andr.70263}
}
EUVIMED